| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/03/2009 | US7498344 E.g., 4-[4-(4-fluoro)phenoxy]pheny-1-(2-phenyl-2-oxoethyl)-4-piperidinol; antiischemic agents; antiepilptic agents; relief of symptoms form seizures and migraines; calcium channel blockers (T-type Ca2+ channel); brain disorders; cardiovascular disorders |
| 03/03/2009 | US7498343 Mycobacterial inhibitors |
| 03/03/2009 | US7498342 Compounds modulating c-kit activity |
| 03/03/2009 | US7498341 antidiabetic agents; type 2 diabetes |
| 03/03/2009 | US7498340 Topoisomerase I inhibitors; improved stability, water solubility, toxicity; anticancer agents; camptothecins bearing an oxime group in position 7; 7-tert-butoxyiminomethyl-20-O-(4-trimethyl-ammonium-3-hydroxy)butanoyl-camptothecin bromide; glioma |
| 03/03/2009 | US7498339 e.g. N-[(4-Chlorophenyl)(phenyl)methyl]-2-oxo-2-(1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-yl)ethanamine; vasopressin V1a receptor antagonist; antidepressant, anxiolytic, hypotensive agent; dysmenorrhea, chronic heart failure, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder |
| 03/03/2009 | US7498338 1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-(2-methoxyphenoxy)propan-2-ol hydrochloride; modulators of chemokine receptor; autoinuune, inflammatory, porliferative diseases; antagonists |
| 03/03/2009 | US7498337 Acid secretion inhibitor |
| 03/03/2009 | US7498336 anticancer agents; to regulate p53 and MDM2 stability and activity; 10-(3-chloro-phenyl)-7-nitro-10H-pyrimido[4,5-b]quinoline-2,4-dione, and 10-(4-chloro-phenyl)-7-nitro-10H-pyrimido[4,5-b]quinoline-2,4-dione |
| 03/03/2009 | US7498335 Method of producing an antiangiogenic or vascular permeability reducing effect |
| 03/03/2009 | US7498334 Pyrrolopyrimidines as phosphodiesterase VII inhibitors |
| 03/03/2009 | US7498333 treatment or prophylaxis of cancer; inhibit the microtubule motor protein HsEg5; N-(3-aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-4,5-dihydroisothiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide |
| 03/03/2009 | US7498332 Therapy for cerebral vasospasm |
| 03/03/2009 | US7498330 4-oxo-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrazine-6-carboxamide compounds |
| 03/03/2009 | US7498329 5-[(2R,5S)-5-methyl-4-propylmorpholin-2-yl]pyridin-2-amine di-S-camsylate useful for treating sexual, neurodegenerative and psychological disorders; 5-(2-(2-hydroxyethylamino)-1-hydroxyethyl)-2-(2,5-dimethyl-1-pyrrolyl)pyridine or salt intermediate |
| 03/03/2009 | US7498328 Derivatives of sulphonamides, their preparation and use as medicaments |
| 03/03/2009 | US7498327 Indolylalkylamine metabolites as 5-hydroxytryptamine-6 ligands |
| 03/03/2009 | US7498326 Gramnegative and Grampositive bacterial infections; substituted Piperidine derivatives specially optionally substituted pyrido [3,2, -b][1,4] thiazin-yl; 6-({(3R,4S)-3-Fluoro-1-[(R)-2-hydroxy-2-(2-methoxy-quinolin-8-yl)-ethyl]-piperidin-4-ylamino }-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one; nontoxic |
| 03/03/2009 | US7498325 Modified amino acids, pharmaceuticals containing these compounds and method for their production |
| 03/03/2009 | US7498324 Substituted lactams as inhibitors of Aβ protein production |
| 03/03/2009 | US7498323 Spiro-piperidine compounds and medicinal use thereof |
| 03/03/2009 | US7498322 Antiangiogenic agents |
| 03/03/2009 | US7498321 17β-carbothioate 17α-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents |
| 03/03/2009 | US7498320 Cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs |
| 03/03/2009 | US7498319 Phosphinic acid derivatives |
| 03/03/2009 | US7498318 Food for diabetics |
| 03/03/2009 | US7498317 Antibacterial agents and process for producing the same |
| 03/03/2009 | US7498316 Nucleic acid with 1st sequence encoding antisense RNAi specific for targeting regions of copper zinc superoxide dismutase that cause inherited amyotrophic lateral sclerosis, and a 2nd sequence encoding a RNAi resistant replacement gene with silent mutations encoding messenger RNA resistant to cleavage |
| 03/03/2009 | US7498315 Oligonucleotide-based therapeutics for the inhibition of oncogenes involved in cancers; non-toxic and effective in low doses |
| 03/03/2009 | US7498314 Expression vectors and uses thereof |
| 03/03/2009 | US7498313 Large circular target-specific antisense nucleic acid compounds |
| 03/03/2009 | US7498312 Compositions containing piperacillin and tazobactam useful for injection |
| 03/03/2009 | US7498311 improvements to avoid high dosage drawbacks of existing compounds; |
| 03/03/2009 | US7498306 E4 or F4 and Bcl-2 peptides of small dimension (less than 30 amino acids) that bind a PP2A holoenzyme or one of its sub-units, particularly useful as anticancer, antiviral and antiparasitic agents |
| 03/03/2009 | US7498304 Angiogenesis-modulating compositions and uses |
| 03/03/2009 | US7498303 The use of at least one GnRH analogue for the preparation of a medicament for the prevention and/or treatment of side effects of ovarectomy or symptoms associated with reproductive senescence in female mammals, in particular |
| 03/03/2009 | US7498302 Analogues of rachelmycin and the duocarmycins that are potent cytotoxins containing a benzodipyrrole or naphthopyrrole ring; anticancer agents |
| 03/03/2009 | US7498301 Administering or applying anserine for treating muscle spasm, localized swelling, inflammation, joint pains, muscle fatigue, stress and myocardial infarction optionally with a diuretic |
| 03/03/2009 | US7498292 Combinatorial libraries of autoinducer analogs, autoinducer agonists and antagonists, and methods of use thereof |
| 03/03/2009 | US7498169 Extending tissue preservation |
| 03/03/2009 | US7498156 Use of visible light at wavelengths of 500 to 550 nm to reduce the number of pathogens in blood and blood components |
| 03/03/2009 | US7498147 Modulating the activity of one or more elements in the complement/lipid pathway |
| 03/03/2009 | US7498146 Containing high-molecular vWF multimers and being free from low-molecular vWF molecules and proteolytic vWF degradation products; chromatographic purification of Factor VIII or a Factor VIII/vWF-complex, admixing a purified high-molecular fraction of vWF molecules; hemophilia A, von Willebrand Disease |
| 03/03/2009 | US7498143 Identification of Actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases |
| 03/03/2009 | US7498128 Methods of determining contributions to metabolic pathways |
| 03/03/2009 | US7498047 Methods for treatment of thiol-containing compound deficient conditions |
| 03/03/2009 | US7498038 Chitin microparticles and their medical uses |
| 03/03/2009 | US7498034 Imaging, diagnosis and treatment of disease |
| 03/03/2009 | US7498025 Targeted bifunctional molecules and therapies based thereon |
| 03/03/2009 | US7498020 Medicaments |
| 03/03/2009 | CA2543986C Norepinephrine reuptake inhibitors and methods of using the same |
| 03/03/2009 | CA2442878C New process for the industrial synthesis of strontium ranelate and its hydrates |
| 03/03/2009 | CA2433714C Arthritis preventing or treating agent |
| 03/03/2009 | CA2422850C High citrate dialysate and uses thereof |
| 03/03/2009 | CA2410880C 2-ethyl and 2-ethylidene-19-nor-vitamin d compounds |
| 03/03/2009 | CA2393197C Control of arthropods in animals with 1-arylpyrazoles |
| 03/03/2009 | CA2356197C Thin polymer film drug reservoirs |
| 03/03/2009 | CA2351617C Method for inhibiting dental resorptive lesions |
| 03/03/2009 | CA2335551C Thyroid hormone analogues and methods for their preparation |
| 03/03/2009 | CA2328348C 2-methylpropionic acid derivatives and medicinal compositions containing the same |
| 03/03/2009 | CA2324904C Topical hormonal composition with systemic effect |
| 03/03/2009 | CA2314173C Therapeutic uses of gaseous mixtures of helium and oxygen, in particular in the treatment of asthma |
| 03/03/2009 | CA2280089C Compositions and methods for reducing ocular hypertension |
| 03/03/2009 | CA2270286C Therapeutic use of an agent that stimulates no or prostacyclin production and delivery device |
| 03/03/2009 | CA2265431C Acetoacetarylamides |
| 03/03/2009 | CA2258165C N-[4-(heteroarylmethyl)phenyl]-heteroarylamines |
| 03/03/2009 | CA2237368C 5'-deoxy-cytidine derivatives |
| 02/28/2009 | CA2597151A1 Hiv vaccine |
| 02/27/2009 | CA2599082A1 Supramacromolecular polymer complexes providing controlled nitric oxide release for healing wounds |
| 02/26/2009 | WO2009026579A1 Proteasome inhibitors and their use in treating pathogen infection and cancer |
| 02/26/2009 | WO2009026544A1 Ampicillin and amoxicillin-based poly(anhydride-amides) |
| 02/26/2009 | WO2009026537A1 Benzylbenzene derivatives and methods of use |
| 02/26/2009 | WO2009026527A1 Novel macrolactam compounds |
| 02/26/2009 | WO2009026517A2 Therapy for complications of diabetes |
| 02/26/2009 | WO2009026496A1 Grp78 and tumor angiogenesis |
| 02/26/2009 | WO2009026473A2 Stabilized therapeutic compositions and formulations |
| 02/26/2009 | WO2009026446A2 Hdac inhibitors |
| 02/26/2009 | WO2009026444A1 Ryanodine channel binders and uses thereof |
| 02/26/2009 | WO2009026434A1 Pulmonary pharmaceutical formulations |
| 02/26/2009 | WO2009026430A2 Liposome formulations of boronic acid compounds |
| 02/26/2009 | WO2009026427A2 Liposome compositions for in vivo administration of boronic acid compounds |
| 02/26/2009 | WO2009026422A2 Treatment of central nervous system disorders |
| 02/26/2009 | WO2009026414A2 Novel application of topical anesthetics for modulation of neurogenic tremor |
| 02/26/2009 | WO2009026408A1 Therapeutic quinoline and naphthalene derivatives |
| 02/26/2009 | WO2009026389A2 Regulating glp-1 and sglt-1 in gastrointestinal cells |
| 02/26/2009 | WO2009026387A1 Poly(ester urethane) urea foams with enhanced mechanical and biological properties |
| 02/26/2009 | WO2009026375A2 Spermicidal and microbicidal compositions |
| 02/26/2009 | WO2009026368A2 Composition and method for managing blood glucose levels, insulin levels and/or insulin receptor functionality |
| 02/26/2009 | WO2009026346A1 Thiazolidine compounds, and methods of making and using same |
| 02/26/2009 | WO2009026345A1 Thiazolidinone compounds, and methods of making and using same |
| 02/26/2009 | WO2009026328A2 Methods of delivery of agents to leukocytes and endothelial cells |
| 02/26/2009 | WO2009026326A1 Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system |
| 02/26/2009 | WO2009026319A1 Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system |
| 02/26/2009 | WO2009026317A2 Use of eif-5a1 sirna to protect islets cells from apoptosis and to preserve their functionality |
| 02/26/2009 | WO2009026315A2 Use of carbon nanotube for drug delivery |
| 02/26/2009 | WO2009026292A1 Dosing methods for treating disease |
| 02/26/2009 | WO2009026276A1 5- (4- (haloalkoxy) phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors |
| 02/26/2009 | WO2009026265A1 A method of extending the dose range of vitamin d compounds |
| 02/26/2009 | WO2009026257A2 Methods and compositions for controlling the bioavailability of poorly soluble drugs |
| 02/26/2009 | WO2009026254A1 Heterocycles as potassium channel modulators |